Monopar Therapeutics Inc. Reports Q2 2025 Net Loss of $2.5 Million, EPS of $0.35, Up from Q2 2024's $1.7 Million Loss and $0.49 EPS
I'm PortAI, I can summarize articles.
Monopar Therapeutics Inc. reported a Q2 2025 net loss of $2.5 million, an increase from a $1.7 million loss in Q2 2024. EPS for Q2 2025 was $0.35, up from $0.49 in the previous year. R&D expenses rose to $1.73 million, driven by higher personnel costs. The company holds $53.3 million in cash and investments, expected to fund operations until December 2026. Monopar is advancing its drug pipeline, including plans for a New Drug Application for ALXN1840 in early 2026 and ongoing clinical trials for MNPR-101.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments